Activity Description/ Purpose
Join the Melanoma DSWG for an insightful webinar and delve into a comprehensive exploration of managing in-transit melanomas, encompassing surgical interventions, regional therapies, injectable/intralesional treatments, and systemic therapy options. The discussion will be enriched by anchoring it with pertinent case studies, providing practical insights and fostering interactive learning.
Faculty
The faculty for this activity are listed below:
Genevieve Boland, MD, PhD (Moderator/Planner)
Harvard Medical School
Georgia Beasley, MD, MHSc (Moderator)
Duke University
James W. Jakub, MD (Faculty Presenter)
Mayo Clinic
Carlo M. Contreras, MD (Faculty Presenter)
The Ohio State University – James Cancer Hospital
Nasreen A. Vohra, MD (Faculty Presenter)
East Carolina University, Brody School of Medicine
Target Audience
This activity is intended for all surgeons and other health care professionals who are involved in the treatment of melanoma cancer patients.
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Understand options for the management of in transit melanoma
- Be familiar with intralesional therapies used for in transit melanoma
- Select and sequence therapy for in transit melanoma
Accreditation
The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The Society of Surgical Oncology designates this internet live course for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Requirements for Earning Credit and Method of Participation
This activity consists of educational content and evaluation. Learners must view the activity content and complete the post-activity evaluation in order to earn credit. A certificate of credit or participation will be available upon successful submission of the post-activity evaluation.
Estimated Time to Complete Activity
The estimated time to complete this entire activity is 1 hour.
Release Date
May 23, 2024
CME Expiration Date
May 23, 2025
Disclosures
As required by the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all planners, reviewers, presenters, instructors, moderators, authors, and other individuals in a position to control or influence the content of an activity must disclose ALL financial relationships with any ineligible company that have occurred within the past 24 months. Ineligible companies are those that cannot be accredited in the ACCME System and whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
As the accredited provider, SSO is responsible for identifying relevant financial relationships between individuals in control of educational content and ineligible companies and managing these to ensure they do not introduce commercial bias into the education. Financial relationships of any dollar amount are defined as relevant if the educational content is related to the business lines or products of the ineligible company.
All identified conflicts of interest must be mitigated, and the educational content vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. If you perceive bias while participating in this activity, please advise us of the circumstances when completing your postactivity evaluation form.
All identified conflicts of interests have been mitigated.
Faculty
Genevieve Boland, MD, PhD has disclosed no financial relationships.
Georgia Beasley, MD, MHSc has disclosed no financial relationships.
James W. Jakub, MD has disclosed no financial relationships.
Carlo M. Contreras, MD has disclosed no financial relationships.
Nasreen A. Vohra, MD has disclosed no financial relationships.
Planners, Reviewers, and Staff
Tania Arora, CME Committee Reviewer, has disclosed no financial relationships.
Patti Stella, CAE, CHCP, Society of Surgical Oncology, has disclosed the following financial relationships - Horizon Therapeutics, SODR Biotech (XBI).
Meagan Gilliland-Johnson, Society of Surgical Oncology, has disclosed no financial relationships.
Devin Winkler, Society of Surgical Oncology, has disclosed no financial relationships.
Disclaimer
The primary purpose of the Society of Surgical Oncology's internet live course is educational. Information, as well as technologies, products, and/or services, discussed are intended to inform participants about the knowledge, techniques, and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty, and the Society of Surgical Oncology disclaims any and all liability for damages to any individual using the materials and for all claims which may result from the use of information, technologies, products, and/or services discussed.
Disclosure of Unlabeled Use
This educational activity may include discussions of unlabeled/unapproved uses of drugs or devices. Participants are advised to refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Opinions expressed in this educational activity are those of the expert contributors and do not necessarily represent the views of the Society of Surgical Oncology or any other organization associated with this activity.
Privacy and Confidentiality
System Requirements
System requirements for this activity can be found by clicking the Help button. For technical support, please contact us at expertED@surgonc.org